conducted in the 1980s, is estimated to run to £15 billion.
The UK government's Sustainable Development Commission (SDC) estimates that this facility could save 5.6 Mt carbon dioxide per year, in comparison to new-built gas-fired power plants. The carbon footprint of building the barrage would be paid back in 5-8 months, according to the SDC. The concept is based on proven technology, as a similar barrage at the river Rance, in Northern France, has operated successfully since 1966.
Even though this would clearly be a significant measure to avoid carbon emissions, environmentalists are up in arms against the idea of a CardiffWeston barrage. It would ensure that large areas that are currently tidal marshland would be permanently under water, and the government admits that "some of the biodiversity would be lost." For this reason, the Royal Society for the Protection of Birds (RSPB) has criticised the decision to include the large barrage in the shortlist.
The Severn estuary, which divides England from southern Wales, has the second largest tidal range in the world, so it seems a natural target to try to harvest tidal energy there, in one of the biggest potential projects to exploit renewable energy Alternative barrage projects could be located further up the river delta, with proportionally smaller impact on the environment and building cost, but also smaller energy generation and carbon dioxide savings. Two such barrage projects are under consideration, generating 1 GW and 0.625 GW, respectively.
Leaving much of the estuary open to the tides, a small barrage could be combined with a 'tidal lagoon' -a walled-off area of water that is connected only to one side of the river delta and thus doesn't block it off. Two such lagoons are on the shortlist, each estimated to generate 1.36 GW. These would still sacrifice some marshland, but would leave the majority of it intact.
Because of the semicircular geometry of the wall that needs to be built around a given volume of water to harvest its flow, these lagoons may turn out to be more expensive to build than barrages of comparable energy output.
Other options left off the government shortlist but favoured by some environmentalists include offshore tidal lagoons and tidal flow turbines. The environmental organisation Friends of the Earth (FoE) has presented a study comparing tidal lagoons with barrage projects. While offshore lagoons would require more building material per water volume reigned in, the fact that they are not connected to rivers or shores would allow the operators to use the tidal range to the maximum and in both directions. While a barrage would only generate hydroelectric power from the water running out to the sea, an enclosed tidal lagoon could be allowed to run completely empty at ebb tide, and thus also to generate electricity while it is refilled with the incoming tide. Based on this two-way mechanism, the FoE study estimates that electricity from a lagoon would end up being more economical than from a barrage.
Upon publication of the government shortlist, FoE voiced strong criticism of the decision not to include offshore lagoons. Gordon James, the director of the Welsh branch of FoE, said: "The development of tidal lagoons would have delivered huge quantities of green power more cheaply and quickly than a barrage, and with less impact on the environment."
The government is now conducting the second phase of its feasibility study, which will look at the technical details and environmental concerns connected to the shortlisted projects and will lead towards a full public consultation in early 2010. If a large barrage project is approved at that point, design and construction work could take up to 12 years to complete.
Michael Gross is a science writer based at Oxford. He can be contacted via his web page at www.michaelgross.co.uk Links: Government: http://www.berr.gov.uk/ energy/severntidalpower FoE: http://www.foe.co.uk/resource/ briefings/severn_barrage_lagoons.pdf
The chief executive of the world's second largest pharmaceutical company, GlaxoSmithKline, has pledged to relax its grip on its intellectual property concerning potentially useful patents for the development of new therapies for treating tropical diseases, as the new European Union trade commissioner pushes ahead for ever stronger global protection for such property.
Andrew Witty, the GSK chief executive, announced a plan last month with four components. The key is to set up a patent pool for medicines for neglected tropical diseases in which GSK would put its small molecule compounds or process patents to allow free access to anyone wanting to develop medicines and products.
The key is to set up a patent pool for medicines for neglected tropical diseases
The aim is to speed up the development of new drugs for Third World diseases such as TB and malaria. However, Witty has ruled out access to patents for HIV/Aids medicines because he says there is already enough innovation in this area.
The other offer from Witty is the plan to sell medicines cheaply to the least-developed countries. Prices will be cut to a quarter of the rates GSK charges in the US and UK -and even less if possible. Along with this is a promise to reinvest 20 per cent of any profits it makes in these countries into their own hospitals, clinics and staff. In addition, drugs would be made more affordable in middle-income countries such as Brazil and India.
He also said GSK will invite scientists from other companies, NGOs or governments to join the hunt for tropical disease treatments at its dedicated institute at Tres Cantos, Spain. Witty, talking to The Guardian, said that his stance "may GlaxoSmithKline wants to share patents and improve drug access in developing countries. Nigel Williams reports.
Patent issues
operates in a number of them and earns there only around £30 million.
Despite the concerns, many still believe Witty's pledge marks a major step forward for neglected diseases and developing countries. "He is breaking the mould in validating the concept of patent pools," said Rohit Malpani at Oxfam's access to medicines campaign. "It is a big step forward. It is welcome that he is inviting other companies to take this on."
But positive moves in the development of medicines by freeing up patents by GSK in certain areas is not a signal for a wider loosening on intellectual property. If anything, Europe is getting tougher in protecting its patents. The EU's trade commissioner, Catherine Ashton, is currently pushing developing countries to accept stringent provisions on intellectual property. This goal "prioritises the rights of patent holders at the expense of access to medicines, jeopardising health in developing countries," writes Monika Kosininska, secretary-general of the European Public Health Alliance in a letter to The Guardian.
"The European Commission has made commitments in multilateral fora, such as the WHO and the WTO's 2001 Doha declaration, to support health in developing countries. The behaviour of Ashton undermines these commitments," she says.
not win him many friends in the other drug companies," but he hoped they would join him in an effort to make a significant difference to the health of people in poor countries.
Médecins Sans Frontières, a leading health NGO, says Witty's price cut for drugs is welcome but not a panacea for availability of drugs. And the charity is also disappointed that HIV/ Aids patents have not been included in the proposed patent pool.
The charity World Vision's director of advocacy, Mike French, said: "Slashing drug prices is good. But, without the necessary health infrastructure, many won't be able to access those drugs. Therefore, investment by GSK, along with the knowledge pooling, makes this a landmark announcement."
Drug companies are criticised for failing to deliver for the rich world as well as the poor. They are often accused of focusing their efforts on making barely altered copies of other companies' billion-dollar sellers rather than working on diseases where there are few treatments, such as Alzheimer's.
Critics of the drug companies acknowledged that in these moves GSK was making major strides but said that it could go further: promising 20 per cent of profits from sales in the least developed countries does not amount to a huge sum as GSK only Shifting: Andrew Witty, chief executive of the pharmaceutical company GSK last month announced a range of measures to try to improve drug development and availability in developing countries. (Photo: GSK.) Have you always been interested in biology? I can't remember a time when I wasn't interested in biology, particularly animal behavior and evolution. My family lived in rural Ohio when I was four or five years old, and I recall spending a lot of time outdoors watching hummingbirds around the big spruce trees next to our house. A more formative moment was when my mother took me to the Cleveland Museum of Natural History and I had the chance to see the 'Lucy' skeleton (Australopithecus afarensis) -at that time the earliest known hominid specimen. This was a truly transformative experience, and generated an intense obsession with primate and human evolution, altogether at odds with my strict Catholic upbringing. Throughout childhood, I kept a set of Time-Life books on 'Evolution', 'The Primates', and 'Animal Behavior' under my bed to read each night before going to
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